Medicenna Therapeutics to Present at Stifel’s Virtual Healthcare Conference
Medicenna Therapeutics Corp. (NASDAQ: MDNA) announces that CEO Dr. Fahar Merchant will present a corporate overview at Stifel’s Virtual Healthcare Conference on November 15, 2021, from 10:00-10:30 a.m. ET. The event aims to provide insights into Medicenna's clinical-stage immunotherapy developments, including MDNA11 and MDNA55, targeted towards enhancing cancer treatment. Details and a link for the webcast will be available on the company's Investor Relations website.
- None.
- None.
TORONTO and HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will be presenting a corporate overview at Stifel’s Virtual Healthcare Conference on Monday, November 15, 2021.
Details are as follows:
Event: Stifel Virtual Healthcare Conference
Format: Corporate Overview
Date: Monday, November 15, 2021
Time: 10:00-10:30 a.m. ET
Webcast Link
Webcast and replay information for these events will be available on the Investor Relations section of Medicenna's website at https://ir.medicenna.com/.
About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.
Forward-Looking Statement
This news release contains forward-looking statements within the meaning of applicable securities laws and relate to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "plan", "expects", "believes" and similar expressions. All statements other than statements of historical fact, included in this release, including the future plans and objectives of the Company, are forward-looking statements that are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the annual information form and Form 40-F of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada and the United States.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.
FAQ
What is Medicenna Therapeutics presenting at the Stifel Virtual Healthcare Conference?
When is Medicenna's presentation at the Stifel Virtual Healthcare Conference?
Where can I find the webcast for Medicenna's conference presentation?
What are the key products Medicenna is focusing on?
What is the stock symbol for Medicenna Therapeutics?
